Observational studyFrontiers in endocrinology2026
The association of triglyceride-glucose body roundness index with carotid atherosclerosis in type 2 diabetes: a cross-sectional study.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The triglyceride-glucose body roundness index (TyG-BRI) has emerged as a promising biomarker correlated with elevated risks of adverse cardiovascular events. Notably, the potential linkage between TyG-BRI and carotid atherosclerosis (CAS) has not been formally evaluated in individuals with type 2 diabetes mellitus. Methods: This cross-sectional observational study consecutively enrolled 1060 adults with type 2 diabetes mellitus in Fujian, China. Anthropometric measurements and fasting venous blood biochemical data were collected to calculate TyG-BRI. CAS was ascertained using high-resolution B-mode ultrasound. Spearman correlation analysis was performed to examine the correlations between TyG-BRI and metabolic indicators. Following stepwise adjustment for confounding variables, hierarchical binary logistic regression and restricted cubic spline curves were applied to evaluate the association of TyG-BRI with CAS risk as well as potential effect modifiers. Finally, receiver operating characteristic (ROC) curve analysis was conducted to evaluate the identification capability of TyG-BRI for CAS. Results: Patients with CAS had significantly higher TyG-BRI levels than non-CAS controls. TyG-BRI was positively correlated with carotid intima-media thickness, glycated hemoglobin (HbA1c), blood pressure, total cholesterol, low-density lipoprotein cholesterol, and uric acid. In fully adjusted models, elevated TyG-BRI was non-linearly associated with higher CAS risk (P for overall association < 0.001, P for non-linearity < 0.01). Per 1-standard-deviation increment in TyG-BRI, the ORs were 1.503 (95% CI 1.281-1.763, P < 0.001) for carotid intima-media thickening, 1.453 (95% CI 1.236-1.709, P < 0.001) for carotid plaque, and 2.247 (95% CI 1.820-2.773, P < 0.001) for CAS. Associations remained consistent across subgroups stratified by age, sex, body mass index (BMI), HbA1c and hypertension, with a stronger effect in participants with BMI < 24 kg/m² (OR 4.838, 95% CI 3.007-7.784, P < 0.001). ROC analysis showed TyG-BRI significantly identified CAS (AUC = 0.698, 95% CI 0.664-0.731, P < 0.001), outperforming TyG and TyG-BMI while matching the performance of the composite indices of TyG combined with waist circumference or waist-to-height ratio. Conclusion: TyG-BRI demonstrated an independent, non-linear dose-response association with CAS risk in type 2 diabetes. Its integration into cardiovascular risk stratification holds promise for enabling earlier identification of CAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.